GFM
AVIR icon

GF Fund Management’s Atea Pharmaceuticals AVIR Stock Holding History

GF Fund Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.7K Sell
1,656
-87
-5% -$433 ﹤0.01% 551
2026
Q1 		$9.38K Buy
1,743
+209
+14% +$960 ﹤0.01% 562
2025
Q4 		$5.48K Sell
1,534
-220
-13% -$699 ﹤0.01% 621
2025
Q3 		$5.09K Sell
1,754
-342
-16% -$1.17K ﹤0.01% 608
2025
Q2 		$7.55K Hold
2,096
– – ﹤0.01% 596
2025
Q1 		$6.27K Buy
2,096
+323
+18% +$1.01K ﹤0.01% 610
2024
Q4 		$5.94K Buy
+1,773
New +$5.89K ﹤0.01% 601

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

GF Fund Management's AVIR Position: Q2 2026 in Review

GF Fund Management reduced its Atea Pharmaceuticals (AVIR) stake by 5% in Q2 2026, selling an estimated $433 and leaving 1,656 shares worth $7.7K. The position accounts for ﹤0.01% of the portfolio, ranked #551.

GF Fund Management first reported a position in AVIR in Q4 2024 and has held it in 7 quarters since. The position peaked at $9.38K in Q1 2026. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • GF Fund Management held 1,656 shares of Atea Pharmaceuticals worth $7.7K as of Q2 2026.
  • GF Fund Management sold 87 Atea Pharmaceuticals shares in Q2 2026, an estimated $433.
  • Atea Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #551 holding.
  • GF Fund Management first reported a position in Atea Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Atea Pharmaceuticals position peaked at $9.38K in Q1 2026.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.